Basal omega-3 fatty acid status affects fatty acid and oxylipin responses to high-dose n3-HUFA in healthy volunteers

Journal of Lipid Research

Volumn 53, Issue 8, 2012, Pages 1662-1669

  Keenan, Alison H ^a   Pedersen, Theresa L ^b   Fillaus, Kristi ^c   Larson, Mark K ^d   Shearer, Gregory C ^c,e   Newman, John W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b AGRICULTURAL RESEARCH SERVICE   (United States)

^c UNIVERSITY OF SOUTH DAKOTA   (United States)

^d AUGUSTANA COLLEGE   (United States)

^e UNIVERSITY OF SOUTH DAKOTA   (United States)

Author keywords

Baseline status; Highly unsaturated fatty acid; Omega 3 fatty acids; Oxylipins; Targetedmetabolomics

Indexed keywords

FATTY ACID; OMEGA 3 FATTY ACID; OXYLIPIN; UNSATURATED FATTY ACID;

ADULT; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CARDIOVASCULAR RISK; CONCENTRATION (PARAMETERS); DIET RESTRICTION; ERYTHROCYTE; ERYTHROCYTE MEMBRANE; FAT INTAKE; FATTY ACID ANALYSIS; FEMALE; FOOD INTAKE; GAS CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NORMAL HUMAN; NUTRITIONAL REQUIREMENT; PRIORITY JOURNAL; RISK REDUCTION; TANDEM MASS SPECTROMETRY; THROMBOCYTE; VOLUNTEER;

ADULT; BASAL METABOLISM; BLOOD PLATELETS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG PRESCRIPTIONS; ERYTHROCYTES; ESTERIFICATION; FATTY ACIDS, OMEGA-3; FEMALE; HEALTH; HUMANS; MALE; MIDDLE AGED; OXYLIPINS; YOUNG ADULT;

EID: 84863792296     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.P025577     Document Type: Article

References (52)

1. McGuire, S. 2011. US Department of Agriculture and US Department of Health and Human Services, Dietary Guidelines for Americans, 2010. 7th Edition, Washington, DC: US Government Printing Office, January 2011. Adv Nutr 2: 293-294.
2. Brunton, S., and N. Collins. 2007. Differentiating prescription omega-3-acid ethyl esters (P-OM3) from dietary-supplement omega- 3 fatty acids. Curr. Med. Res. Opin. 23: 1139-1145. (Pubitemid 46799598)
3. Breslow, J. L. 2006. n-3 fatty acids and cardiovascular disease. Am. J. Clin. Nutr. 83: 1477S-1482S. (Pubitemid 44713088)
4. Ebrahimi, M., M. Ghayour-Mobarhan, S. Rezaiean, M. Hoseini, S. M. Parizade, F. Farhoudi, S. J. Hosseininezhad, S. Tavallaei, A. Vejdani, M. Azimi-Nezhad, et al. 2009. Omega-3 fatty acid supplements improve the cardiovascular risk profile of subjects with metabolic syndrome, including markers of inflammation and autoimmunity. Acta Cardiol. 64: 321-327.
5. Harris, W. S., M. Miller, A. P. Tighe, M. H. Davidson, and E. J. Schaefer. 2008. Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. Atherosclerosis. 197: 12-24.
6. Harris, W. S., H. N. Ginsberg, N. Arunakul, N. S. Shachter, S. L. Windsor, M. Adams, L. Berglund, and K. Osmundsen. 1997. Safety and efficacy of Omacor in severe hypertriglyceridemia. J. Cardiovasc. Risk. 4: 385-391. (Pubitemid 28078682)
7. Davidson, M. H., E. A. Stein, H. E. Bays, K. C. Maki, R. T. Doyle, R. A. Shalwitz, C. M. Ballantyne, and H. N. Ginsberg. 2007. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin. Ther. 29: 1354-1367. (Pubitemid 47348116)
8. Calder, P. C. 2006. Polyunsaturated fatty acids and inflammation. Prostaglandins Leukot. Essent. Fatty Acids. 75: 197-202. (Pubitemid 44292527)
9. Lankinen, M., U. Schwab, A. Erkkila, T. Seppanen-Laakso, M. L. Hannila, H. Mussalo, S. Lehto, M. Uusitupa, H. Gylling, and M. Oresic. 2009. Fatty fish intake decreases lipids related to inflammation and insulin signaling-a lipidomics approach. PLoS ONE. 4: e5258.
10. Weylandt, K. H., A. Nadolny, L. Kahlke, T. Kohnke, C. Schmocker, J. Wang, G. Y. Lauwers, J. N. Glickman, and J. X. Kang. 2008. Reduction of inflammation and chronic tissue damage by omega- 3 fatty acids in fat-1 transgenic mice with pancreatitis. Biochim. Biophys. Acta. 1782: 634-641.
11. Leaf, A., and P. C. Weber. 1988. Cardiovascular effects of n-3 fatty acids. N. Engl. J. Med. 318: 549-557. (Pubitemid 18083576)
12. Larson, M. K., G. C. Shearer, J. H. Ashmore, J. M. Anderson-Daniels, E. L. Graslie, J. T. Tholen, J. L. Vogelaar, A. J. Korth, V. Nareddy, M. Sprehe, et al. 2011. Omega-3 fatty acids modulate collagen signaling in human platelets. Prostaglandins Leukot. Essent. Fatty Acids. 84: 93-98.
13. Dubnov, G., and E. M. Berry. 2004. Omega-6 fatty acids and coronary artery disease: the pros and cons. Curr. Atheroscler. Rep. 6: 441-446. (Pubitemid 39585668)
14. Harris, W. S., D. Mozaffarian, E. Rimm, P. Kris-Etherton, L. L. Rudel, L. J. Appel, M. M. Engler, M. B. Engler, and F. Sacks. 2009. Omega-6 fatty acids and risk for cardiovascular disease: a science advisory from the American Heart Association Nutrition Subcommittee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Cardiovascular Nursing; and Council on Epidemiology and Prevention. Circulation. 119: 902-907.
15. Toledo, L., L. Masgrau, J. D. Marechal, J. M. Lluch, and A. Gonzalez- Lafont. 2010. Insights into the mechanism of binding of arachidonic acid to mammalian 15-lipoxygenases. J. Phys. Chem. B. 114: 7037-7046.
16. Harris, W. S. 2008. The omega-3 index as a risk factor for coronary heart disease. Am. J. Clin. Nutr. 87: 1997S-2002S. (Pubitemid 351872681)
17. von Schacky, C., and W. S. Harris. 2007. Cardiovascular risk and the omega-3 index. J. Cardiovasc. Med. (Hagerstown). 8 (Suppl 1) : S46-S49.
18. Burrows, T., C. E. Collins, and M. L. Garg. 2011. Omega-3 index, obesity and insulin resistance in children. Int. J. Pediatr. Obes. 6: e532-e539.
19. Baghai, T. C., G. Varallo-Bedarida, C. Born, S. Hafner, C. Schule, D. Eser, R. Rupprecht, B. Bondy, and C. von Schacky. 2011. Major depressive disorder is associated with cardiovascular risk factors and low Omega-3 index. J. Clin. Psychiatry. 72: 1242-1247.
20. O'Sullivan, T. A., G. L. Ambrosini, T. A. Mori, L. J. Beilin, and W. H. Oddy. 2011. Omega-3 index correlates with healthier food consumption in adolescents and with reduced cardiovascular disease risk factors in adolescent boys. Lipids. 46: 59-67.
21. Harris, W. S. 2010. The omega-3 index: clinical utility for therapeutic intervention. Curr. Cardiol. Rep. 12: 503-508.
22. Shearer, G. C., W. S. Harris, T. L. Pedersen, and J. W. Newman. 2010. Detection of omega-3 oxylipins in human plasma and response to treatment with omega-3 acid ethyl esters. J. Lipid Res. 51: 2074-2081.
23. Larson, M. K., J. H. Ashmore, K. A. Harris, J. L. Vogelaar, J. V. Pottala, M. Sprehe, and W. S. Harris. 2008. Effects of omega-3 acid ethyl esters and aspirin, alone and in combination, on platelet function in healthy subjects. Thromb. Haemost. 100: 634-641.
24. Guillot, N., E. Caillet, M. Laville, C. Calzada, M. Lagarde, and E. Vericel. 2009. Increasing intakes of the long-chain omega-3 docosahexaenoic acid: effects on platelet functions and redox status in healthy men. FASEB J. 23: 2909-2916.
25. Calzada, C., R. Colas, N. Guillot, M. Guichardant, M. Laville, E. Vericel, and M. Lagarde. 2010. Subgram daily supplementation with docosahexaenoic acid protects low-density lipoproteins from oxidation in healthy men. Atherosclerosis. 208: 467-472.
26. Block, R. C., W. S. Harris, K. J. Reid, S. A. Sands, and J. A. Spertus. 2008. EPA and DHA in blood cell membranes from acute coronary syndrome patients and controls. Atherosclerosis. 197: 821-828. (Pubitemid 351417881)
27. Hochberg, Y., and Y. Benjamini. 1990. More powerful procedures for multiple significance testing. Stat. Med. 9: 811-818. (Pubitemid 20343989)
28. Barnett, A. G., J. C. van der Pols, and A. J. Dobson. 2005. Regression to the mean: what it is and how to deal with it. Int. J. Epidemiol. 34: 215-220. (Pubitemid 40347398)
29. Saleem, T. 2009. Role of omega-3 fatty acids in improving health. J. Pak. Med. Assoc. 59: 864-865.
30. Calder, P. C., and P. Yaqoob. 2009. Omega-3 polyunsaturated fatty acids and human health outcomes. Biofactors. 35: 266-272.
31. Deckelbaum, R. J., T. S. Worgall, and T. Seo. 2006. n-3 fatty acids and gene expression. Am. J. Clin. Nutr. 83: 1520S-1525S. (Pubitemid 44713093)
32. Powell, W. S., S. Gravel, and F. Gravelle. 1995. Formation of a 5-oxo metabolite of 5,8,11,14,17-eicosapentaenoic acid and its effects on human neutrophils and eosinophils. J. Lipid Res. 36: 2590-2598. (Pubitemid 26029615)
33. Serhan, C. N. 2005. Novel eicosanoid and docosanoid mediators: resolvins, docosatrienes, and neuroprotectins. Curr. Opin. Clin. Nutr. Metab. Care. 8: 115-121. (Pubitemid 40289470)
34. Morisseau, C., B. Inceoglu, K. Schmelzer, H. J. Tsai, S. L. Jinks, C. M. Hegedus, and B. D. Hammock. 2010. Naturally occurring monoepoxides of eicosapentaenoic acid and docosahexaenoic acid are bioactive antihyperalgesic lipids. J. Lipid Res. 51: 3481-3490.
35. el Boustani, S., C. Colette, L. Monnier, B. Descomps, A. Crastes de Paulet, and F. Mendy. 1987. Enteral absorption in man of eicosapentaenoic acid in different chemical forms. Lipids. 22: 711-714. (Pubitemid 18066900)
36. Nordoy, A., L. Barstad, W. E. Connor, and L. Hatcher. 1991. Absorption of the n-3 eicosapentaenoic and docosahexaenoic acids as ethyl esters and triglycerides by humans. Am. J. Clin. Nutr. 53: 1185-1190.
37. Goodnight, S. H., Jr., W. S. Harris, and W. E. Connor. 1981. The effects of dietary omega 3 fatty acids on platelet composition and function in man: a prospective, controlled study. Blood. 58: 880-885.
38. Prisco, D., M. Filippini, I. Francalanci, R. Paniccia, G. F. Gensini, K. Abbate, and G. G. Neri Serneri. 1996. Effect of n-3 polyunsaturated fatty acid intake on phospholipid fatty acid composition in plasma and erythrocytes. Am. J. Clin. Nutr. 63: 925-932. (Pubitemid 26173243)
39. Cartwright, I. J., A. G. Pockley, J. H. Galloway, M. Greaves, and F. E. Preston. 1985. The effects of dietary omega-3 polyunsaturated fatty acids on erythrocyte membrane phospholipids, erythrocyte deformability and blood viscosity in healthy volunteers. Atherosclerosis. 55: 267-281. (Pubitemid 15000530)
40. Aukema, H. M., and B. J. Holub. 1989. Effect of dietary supplementation with a fish oil concentrate on the alkenylacyl class of ethanolamine phospholipid in human platelets. J. Lipid Res. 30: 59-64. (Pubitemid 19037566)
41. Jiang, H., G. D. Anderson, and J. C. McGiff. 2010. Red blood cells (RBCs), epoxyeicosatrienoic acids (EETs) and adenosine triphosphate (ATP). Pharmacol. Rep. 62: 468-474.
42. Saraswathi, V., L. Gao, J. D. Morrow, A. Chait, K. D. Niswender, and A. H. Hasty. 2007. Fish oil increases cholesterol storage in white adipose tissue with concomitant decreases in inflammation, hepatic steatosis, and atherosclerosis in mice. J. Nutr. 137: 1776-1782. (Pubitemid 47037706)
43. Gonzalez-Periz, A., A. Planaguma, K. Gronert, R. Miquel, M. Lopez- Parra, E. Titos, R. Horrillo, N. Ferre, R. Deulofeu, V. Arroyo, et al. 2006. Docosahexaenoic acid (DHA) blunts liver injury by conversion to protective lipid mediators: protectin D1 and 17S-hydroxy-DHA. FASEB J. 20: 2537-2539.
44. VanRollins, M. 1995. Epoxygenase metabolites of docosahexaenoic and eicosapentaenoic acids inhibit platelet aggregation at concentrations below those affecting thromboxane synthesis. J. Pharmacol. Exp. Ther. 274: 798-804.
45. Morin, C., M. Sirois, V. Echave, E. Rizcallah, and E. Rousseau. 2009. Relaxing effects of 17(18)-EpETE on arterial and airway smooth muscles in human lung. Am. J. Physiol. Lung Cell. Mol. Physiol. 296: L130-L139.
46. Zou, A. P., J. T. Fleming, J. R. Falck, E. R. Jacobs, D. Gebremedhin, D. R. Harder, and R. J. Roman. 1996. Stereospecific effects of epoxyeicosatrienoic acids on renal vascular tone and K(+)-channel activity. Am. J. Physiol. 270: F822-F832. (Pubitemid 26178768)
47. Behm, D. J., A. Ogbonna, C. Wu, C. L. Burns-Kurtis, and S. A. Douglas. 2009. Epoxyeicosatrienoic acids function as selective, endogenous antagonists of native thromboxane receptors: identification of a novel mechanism of vasodilation. J. Pharmacol. Exp. Ther. 328: 231-239.
48. Xiang, L., J. S. Naik, and R. L. Hester. 2008. Functional vasodilation in the rat spinotrapezius muscle: role of nitric oxide, prostanoids and epoxyeicosatrienoic acids. Clin. Exp. Pharmacol. Physiol. 35: 617-624. (Pubitemid 351490103)
49. Atkins, P. W., and J. De Paula. 2006. Atkins' physical chemistry. 8th ed. Oxford University Press, Oxford; New York.
50. Luxwolda, M. F., R. S. Kuipers, E. N. Smit, F. V. Velzing-Aarts, D. A. Janneke Dijck-Brouwer, and F. A. Muskiet. 2011. The relation between the omega-3 index and arachidonic acid is bell shaped: synergistic at low EPA+DHA status and antagonistic at high EPA+DHA status. Prostaglandins Leukot. Essent. Fatty Acids. 85: 171-178.
51. Pearson, E. S. 1967. Studies in the history of probability and statistics. XVII. Some reflexions on continuity in the development of mathematical statistics, 1885-1920. Biometrika. 54: 341-355.
52. Harris, W. S., and C. Von Schacky. 2004. The omega-3 index: a new risk factor for death from coronary heart disease? Prev. Med. 39: 212-220. (Pubitemid 38797975)